• 1.

    Danila. Renal damage is the most important predictor of mortality: Data from a multiethnic US cohort. Rheumatology 2009; 48:542545.

  • 2.

    Gourley MF, et al.. Methylprednisolone and cyclophosphamide, alone or in combination in patients with lupus nephritis: A RCT. Ann Intern Med 1996; 125:549557.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Houssiau FA, et al.. Immunosuppressive therapy in lupus nephritis: The Eurolupus Nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:21212131.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Appel GB, et al.. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20:11031112.

  • 5.

    Contreras G, et al.. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971980.

  • 6.

    Houssiau FA, et al.. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69:20832089.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Dooley MA, et al.. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:18861889.

  • 8.

    Rovin. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. N Engl J Med 2012; 64:12151226.

  • 9.

    Weidenbusch. Beyond the LUNAR trial: Efficacy of rituximab in refractory lupus nephritis. Transplantation 2013; 28:106111.

  • 10.

    Austin HA 3rd, et al.. Randomized controlled trial of prednisone, cyclophosphamide and cyclosporine in lupus membranous nephritis. J Am Soc Nephrol 2009; 20:901911.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Radhakrishnan J, et al.. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010; 77:152160.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Condon MB, et al.. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate but no oral steroids. Ann Rheum Dis 2013; 72:12801286.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Lui. Multitargeted treatment for induction of lupus nephritis: A randomized trial. Ann Intern Med 2015; 162:1826.

  • 14.

    Rönnblom L, Alm GV, Eloranta ML. The type I interferon assists in the development of lupus. Semin Immunol 2011; 23:113121.

  • 15.

    Feng X, et al.. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:29512962.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Furie R, et al.. Anifrolumab, an anti–interferon-alpha receptor monoclonal antibody in moderate to severe SLE. Arthritis Rheum 2017; 69:376386.

  • 17.

    Mossner E, et al.. Increasing the efficacy of CD20 antibody therapy through engineering a new type 2 anti-20 antibody with enhanced direct and immune effector cell mediated B cell cytotoxicity. Blood 2010; 115:43934402.

    • Crossref
    • Search Google Scholar
    • Export Citation

Lupus Nephritis in 2017: An Update

  • 1 Wai Lang Lau, MD, is instructor of medicine and glomerular fellow, and
  • | 2 Gerald Appel MD, FASN, is professor of medicine at the Glomerular Center of Columbia University College of Physicians and Surgeons.
Restricted access
Save